Adaptive Nivolumab Plus Ipilimumab Improves Outcomes in mRCC
Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy.
Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy.
Clear management guidelines are needed for AKI during immune checkpoint inhibitor therapy, according to investigators.
Study included a large, contemporary cohort of patients with T1a renal cell carcinoma undergoing partial nephrectomy or local tumor destruction.
Adjuvant pembrolizumab could be a new standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, according to researchers.
Study revealed an objective response rate consistent with that observed in the CheckMate 214 clinical trial and a low rate of treatment-related adverse events.
Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
The PFS benefit was driven primarily by patients with intermediate-risk disease.
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.
An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.